Looking on the internet for info on the side effects on the side effects on AstraZeneca vaccine
Yellow Card reporting info , https://coronavirus-yellowcard.mhra.gov.uk/
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1012208/COVID-19_vaccine_AstraZeneca_analysis_print_final.pdf
I found this...
https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca
Published 30 December 2020
Last updated 20 August 2021
Updated the PIL and Spc to include new warning on Guillaine-Barre Syndrome
Added Lay summary, Vaxzevria (previously COVID‑19 Vaccine AstraZeneca, suspension for injection) COVID-19 Vaccine (ChAdOx1‑S [recombinant])
Updated to reflect the addition of capillary leak syndrome as a contraindication. Also changed the name of the COVID-19 Vaccine AstraZeneca in the Conditional Marketing Authorisation product information to the brand name - Vaxzevria.
A Summary of Product Information, a Patient Information Leaflet and a Conditions of Authorisation for COVID-19 Vaccine AstraZeneca Conditional Marketing Authorisation have been added as the MHRA has issued a Conditional Marketing Authorisation for the vaccine. Updated versions of the Information for healthcare professionals and Information for UK recipients documents have also been added.
Updated the Information for Healthcare Professionals and Information for UK Recipients on COVID-19 Vaccine AstraZeneca with new information about extremely rare, unlikely to occur blood clots.
Updated the Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca, with new information about extremely rare, unlikely to occur blood clots.
All documents were updated to include updated side effect frequency and efficacy data, including a new table on efficacy by dosing interval in the Information for UK Healthcare Professionals document. A new Annex (Annex 1: Addition of manufacturer and importer) was added to the Conditions of Authorisation document.
Published new versions of the Conditions of Authorisation documents, with an additional clause relating to off-label prescribing
Published a new version of the Information for UK healthcare professionals, adding new information in Section 6.6 allowing for an additional dose to be taken if there is sufficient for a further full dose to be taken from the vial.
Added an accessible HTML version of the summary of the Public Assessment Report
Publication of Public Assessment Report for AztraZeneca COVID-19 vaccine
First published.
~ ~ ~ ~
No comments:
Post a Comment